Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, two highly specific blood markers, which improve disease differentiation and early detection when combined. Their multiplex protein profiling technology allows simultaneous measurement of tau pathology, neuroinflammation, and neurodegeneration markers, offering deeper insights into Alzheimer's progression. Alamar also hosted a workshop to discuss these innovations, signaling growing adoption of their technology in Alzheimer's research.
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
Bitcoin governance controversy has resurfaced as David Bailey accused developer Luke Dashjr of introducing a blacklist in 2014 Gentoo Bitcoin software, blocking gambling transactions. Dashjr now advocates BIP-110, aiming to restrict non-financial dat...
Halper Sadeh LLC is investigating whether shareholders of Simulations Plus (SLP), Huntsman Corporation (HUN), Olin Corporation (OLN), and Pulmatrix (PULM) are receiving fair deals in recent mergers and sales. The firm suspects insiders may gain finan...
Bitcoin has rebounded sharply from recent lows and is now approaching a key resistance level at $65,400, marked by the 50-day exponential moving average (EMA). This level has previously blocked upward momentum, so a successful breakout could lead to ...
